Hao Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hao Pan has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Gary E. Schiltz
Department of Chemistry, Northwestern University, Evanston, IL 60208, USA
3 shared publications - Songhua Quan
Department of Urology, Northwestern University Feinberg School of Medicine; Chicago, IL, USA
3 shared publications - Adam W. T. Steffeck
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
2 shared publications - Debabrata Chakravarti
The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine; Chicago, IL, USA
2 shared publications - Dikshat Gopal Gupta
Department of Urology, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
2 shared publications - Megan M. Kerber
Department of Urology, Northwestern University Feinberg School of Medicine; Chicago, IL, USA
2 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4468-4482
PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells
Acute myeloid leukemia (AML) is an aggressive hematological malignancy that is sustained by leukemia-initiating cells (LICs). Although protein tyrosine phosphatase 4A2 (PTP4A2), also known as phosphatase of regenerating liver 2 (PRL2), is highly expressed in AML, the mechanisms by which PTP4A2 promotes leukemogenesis are largely unexplored. In this study, we demonstrate that PTP4A2 promotes AML by inhibiting the p53 tumor suppressor pathway in LICs. Using KMT2A-MLLT3–driven AML as a model, we found that PTP4A2 deficiency activates p53 and induces LIC apoptosis and senescence, thereby extending the survival of recipient mice repopulated with Ptp4a2−/− LICs. Mechanistically, PTP4A2 directly interacts with p53 and dephosphorylates it at serine 392, decreasing p53 stability and activity to enhance LIC proliferation and survival. Collectively, our findings identify p53 as a potential PTP4A2 substrate in leukemia cells and uncover a novel mechanism by which PTP4A2 enhances LIC maintenance.
- 14 July 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4468-4482
Open AccessPTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells
Acute myeloid leukemia (AML) is an aggressive hematological malignancy that is sustained by leukemia-initiating cells (LICs). Although protein tyrosine phosphatase 4A2 (PTP4A2), also known as phosphatase of regenerating liver 2 (PRL2), is highly expressed in AML, the mechanisms by which PTP4A2 promotes leukemogenesis are largely unexplored. In this study, we demonstrate that PTP4A2 promotes AML by inhibiting the p53 tumor suppressor pathway in LICs. Using KMT2A-MLLT3–driven AML as a model, we found that PTP4A2 deficiency activates p53 and induces LIC apoptosis and senescence, thereby extending the survival of recipient mice repopulated with Ptp4a2−/− LICs. Mechanistically, PTP4A2 directly interacts with p53 and dephosphorylates it at serine 392, decreasing p53 stability and activity to enhance LIC proliferation and survival. Collectively, our findings identify p53 as a potential PTP4A2 substrate in leukemia cells and uncover a novel mechanism by which PTP4A2 enhances LIC maintenance.
- Open Access
A bivalent lysine-acetylated small-molecule binding site in MYC
MYC is an important, yet challenging target in oncology as it lacks traditional “druggable” pockets. Here we show that two regions of the MYC protein, the basic-Helix-Loop-Helix (bHLH) domain, and an extended MYC Box II (eMBII) come together to form a bivalent, high-affinity small-molecule MYC inhibitor (MYCi) binding site. CRISPR-tiling mutagenesis identified mutations in the vicinity of emBII and in bHLH regions that together confer MYCi resistance. Importantly, acetylation of lysine K148 in eMBII which is essential for MYC oncogenicity in vivo increased the predicted order of this region and enhanced MYCi binding affinity. Furthermore, MYCi selectively modulated the expression of the same genes regulated by lysine-acetylated MYC in cancer cells. These studies provide a rationale for the selective targeting of acetylated, oncogenic MYC with small molecules.
Open AccessA bivalent lysine-acetylated small-molecule binding site in MYC
MYC is an important, yet challenging target in oncology as it lacks traditional “druggable” pockets. Here we show that two regions of the MYC protein, the basic-Helix-Loop-Helix (bHLH) domain, and an extended MYC Box II (eMBII) come together to form a bivalent, high-affinity small-molecule MYC inhibitor (MYCi) binding site. CRISPR-tiling mutagenesis identified mutations in the vicinity of emBII and in bHLH regions that together confer MYCi resistance. Importantly, acetylation of lysine K148 in eMBII which is essential for MYC oncogenicity in vivo increased the predicted order of this region and enhanced MYCi binding affinity. Furthermore, MYCi selectively modulated the expression of the same genes regulated by lysine-acetylated MYC in cancer cells. These studies provide a rationale for the selective targeting of acetylated, oncogenic MYC with small molecules.
- 13 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (4) , 4439-4468
Development of DOT1L-Targeted Protein Degraders for Treating MLL-r Leukemia
DOT1L is aberrantly recruited in MLL-r leukemias and serves as a critical oncogenic driver. Substantial previous work has developed catalytic inhibitors like pinometostat, which showed limited clinical efficacy. Recent work has defined nonenzymatic functions of DOT1L in promoting leukemia progression. Because these functions cannot be blocked by enzymatic inhibitors, we developed novel DOT1L-targeting PROTACs (Proteolysis-Targeting Chimeras ) to degrade the protein and thereby block all of its functions. We describe PROTACs DOT1L705 and DOT1L808 as potent and highly selective DOT1L degraders with DC50 values of 0.33 μM and 5 nM, respectively. The effect of DOT1L705 on cell viability is highly dependent on the MLL-r status of leukemia cell lines, and it retains activity against menin inhibitor-resistant cells. In vivo studies with DOT1L808 showed its ability to achieve complete tumor regression in an orthotopic leukemia model without overt toxicity. These results establish protein degradation as a promising therapeutic strategy for MLL-rearranged leukemias.
- 13 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (4) , 4439-4468
Development of DOT1L-Targeted Protein Degraders for Treating MLL-r Leukemia
DOT1L is aberrantly recruited in MLL-r leukemias and serves as a critical oncogenic driver. Substantial previous work has developed catalytic inhibitors like pinometostat, which showed limited clinical efficacy. Recent work has defined nonenzymatic functions of DOT1L in promoting leukemia progression. Because these functions cannot be blocked by enzymatic inhibitors, we developed novel DOT1L-targeting PROTACs (Proteolysis-Targeting Chimeras ) to degrade the protein and thereby block all of its functions. We describe PROTACs DOT1L705 and DOT1L808 as potent and highly selective DOT1L degraders with DC50 values of 0.33 μM and 5 nM, respectively. The effect of DOT1L705 on cell viability is highly dependent on the MLL-r status of leukemia cell lines, and it retains activity against menin inhibitor-resistant cells. In vivo studies with DOT1L808 showed its ability to achieve complete tumor regression in an orthotopic leukemia model without overt toxicity. These results establish protein degradation as a promising therapeutic strategy for MLL-rearranged leukemias.
- Open Access
- 18 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (29) , eadw5228
Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors
MYC is a key driver in many aggressive and therapy-resistant cancers. We have developed and characterized a small-molecule MYC inhibitor named MYCi975. To uncover combination strategies for MYC inhibitors, we conducted a genome-wide CRISPR screen using MYCi975. This screen revealed a notable synthetic lethality when MYC inhibition was paired with disruption of mitochondrial complex I components, but not other complexes. Mechanistically, MYC inhibition reduced oxidative phosphorylation and glycolysis, triggering a compensatory up-regulation of complex I genes. Consequently, genetic or pharmacological targeting of complex I sensitized tumors to MYCi975 treatment, leading to increased purine catabolism and infiltration of CD8 + T cells and macrophages into tumors. Additionally, a wide range of tumor cells with lower complex I expression showed increased MYC dependency. These results indicate that metabolic adaptation to MYC inhibition exposes a targetable weakness at complex I and provide a rational strategy for combination therapy with emerging MYC inhibitors.
- 18 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (29) , eadw5228
Open AccessImpaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors
MYC is a key driver in many aggressive and therapy-resistant cancers. We have developed and characterized a small-molecule MYC inhibitor named MYCi975. To uncover combination strategies for MYC inhibitors, we conducted a genome-wide CRISPR screen using MYCi975. This screen revealed a notable synthetic lethality when MYC inhibition was paired with disruption of mitochondrial complex I components, but not other complexes. Mechanistically, MYC inhibition reduced oxidative phosphorylation and glycolysis, triggering a compensatory up-regulation of complex I genes. Consequently, genetic or pharmacological targeting of complex I sensitized tumors to MYCi975 treatment, leading to increased purine catabolism and infiltration of CD8 + T cells and macrophages into tumors. Additionally, a wide range of tumor cells with lower complex I expression showed increased MYC dependency. These results indicate that metabolic adaptation to MYC inhibition exposes a targetable weakness at complex I and provide a rational strategy for combination therapy with emerging MYC inhibitors.
- 28 March 2024
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 220, 106926
Single primer site-specific nested PCR for accurate and rapid genome-walking
- 28 March 2024
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 220, 106926
Single primer site-specific nested PCR for accurate and rapid genome-walking
- Open Access
- 7 December 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
A method for low-coverage single-gamete sequence analysis demonstrates adherence to Mendel’s first law across a large sample of human sperm
Recently published single-cell sequencing data from individual human sperm (n=41,189; 969–3377 cells from each of 25 donors) offer an opportunity to investigate questions of inheritance with improved statistical power, but require new methods tailored to these extremely low-coverage data (∼0.01× per cell). To this end, we developed a method, named rhapsodi, that leverages sparse gamete genotype data to phase the diploid genomes of the donor individuals, impute missing gamete genotypes, and discover meiotic recombination breakpoints, benchmarking its performance across a wide range of study designs. We then applied rhapsodi to the sperm sequencing data to investigate adherence to Mendel’s Law of Segregation, which states that the offspring of a diploid, heterozygous parent will inherit either allele with equal probability. While the vast majority of loci adhere to this rule, research in model and non-model organisms has uncovered numerous exceptions whereby ‘selfish’ alleles are disproportionately transmitted to the next generation. Evidence of such ‘transmission distortion’ (TD) in humans remains equivocal in part because scans of human pedigrees have been under-powered to detect small effects. After applying rhapsodi to the sperm data and scanning for evidence of TD, our results exhibited close concordance with binomial expectations under balanced transmission. Together, our work demonstrates that rhapsodi can facilitate novel uses of inferred genotype data and meiotic recombination events, while offering a powerful quantitative framework for testing for TD in other cohorts and study systems.
- 7 December 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Open AccessA method for low-coverage single-gamete sequence analysis demonstrates adherence to Mendel’s first law across a large sample of human sperm
Recently published single-cell sequencing data from individual human sperm (n=41,189; 969–3377 cells from each of 25 donors) offer an opportunity to investigate questions of inheritance with improved statistical power, but require new methods tailored to these extremely low-coverage data (∼0.01× per cell). To this end, we developed a method, named rhapsodi, that leverages sparse gamete genotype data to phase the diploid genomes of the donor individuals, impute missing gamete genotypes, and discover meiotic recombination breakpoints, benchmarking its performance across a wide range of study designs. We then applied rhapsodi to the sperm sequencing data to investigate adherence to Mendel’s Law of Segregation, which states that the offspring of a diploid, heterozygous parent will inherit either allele with equal probability. While the vast majority of loci adhere to this rule, research in model and non-model organisms has uncovered numerous exceptions whereby ‘selfish’ alleles are disproportionately transmitted to the next generation. Evidence of such ‘transmission distortion’ (TD) in humans remains equivocal in part because scans of human pedigrees have been under-powered to detect small effects. After applying rhapsodi to the sperm data and scanning for evidence of TD, our results exhibited close concordance with binomial expectations under balanced transmission. Together, our work demonstrates that rhapsodi can facilitate novel uses of inferred genotype data and meiotic recombination events, while offering a powerful quantitative framework for testing for TD in other cohorts and study systems.
- Open Access
- 12 March 2012
- Published by American Physical Society (APS) in Physical Review B
- Vol. 85 (9)
Erratum: Lattice constants from semilocal density functionals with zero-point phonon correction [Phys. Rev. B85, 014111 (2012)]
DOI: http://dx.doi.org/10.1103/PhysRevB.85.099903 ©2012 American Physical Society
- 12 March 2012
- Published by American Physical Society (APS) in Physical Review B
- Vol. 85 (9)
Open AccessErratum: Lattice constants from semilocal density functionals with zero-point phonon correction [Phys. Rev. B85, 014111 (2012)]
DOI: http://dx.doi.org/10.1103/PhysRevB.85.099903 ©2012 American Physical Society